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Tocilizumab (TCZ) is the first FDA- approved treatment for systemic juvenile idiopathic arthritis (sJIA). We report 3
cases of cytopenias in children with sJIA treated with TCZ. Two of the children who developed significant
cytopenias shortly after initiation of TCZ had a history of macrophage activation syndrome. We raise the possibility
that patients with a tendency towards MAS have an increased risk of developing cytopenias when treated with
tocilizumab.
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Systemic juvenile idiopathic arthritis (sJIA) is a subtype
of chronic childhood arthritis of unknown etiology that
is characterized by spiking fever, rash, generalized
lymphadenopathy, hepatosplenomegaly, and serositis [1].
About 7% of sJIA patients develop macrophage activa-
tion syndrome (MAS), which is due to excessive activa-
tion of macrophages and T cells leading to a profound
inflammatory reaction. Like sJIA, MAS manifests as
fever (though more persistent as compared to sJIA),
lymphadenopathy, and hepatosplenomegaly. Addition-
ally, patients with MAS can have significant cytopenias,
liver dysfunction, and serious coagulopathies [2]. Tocili-
zumab (TCZ), an anti-interleukin (IL)-6 receptor anti-
body, is the first FDA- approved treatment for sJIA.
Prior studies of TCZ have not reported the development
of significant cytopenias requiring medication discon-
tinuance [3-5]. We report 3 cases of cytopenias in chil-
dren with sJIA treated with TCZ necessitating a dose
reduction or discontinuation of the drug. The 2 children
who had a history of recurrent MAS developed* Correspondence: jverbsky@mcw.edu
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reproduction in any medium, provided the orsignificant cytopenias soon after initiation of TCZ. All
three children were dosed according to manufacture
guidelines; for patients <30 kg, 12 mg/kg was given every
two weeks and for those ≥ 30 kg, 8 mg/kg was given
every two weeks.Case presentations
Case 1
A 6 year-old Caucasian girl with a 6 month history of sJIA
was started on twice monthly TCZ therapy (12 mg/kg/
dose) after failed treatment with methotrexate, adalimu-
mab, and rilonacept due to persistent arthritis and inability
to wean steroids. After 5 transfusions of tocilizumab over a
twelve week period, her absolute neutrophil count (ANC)
dropped from 13,900 to 800 cells/μL. Platelet count,
erythrocyte sedimentation rate (ESR) and C-reactive pro-
tein concentration (CRP) normalized (Figure 1A). As the
patient was otherwise clinically well when she became neu-
tropenic, further laboratory studies were not obtained.
Methotrexate and TCZ were held for two weeks until the
neutropenia resolved. Methotrexate was resumed and her
TCZ dose was subsequently decreased to 8 mg/kg/dose
and administered every three weeks without further inci-
dent over a 10 month follow-up period.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Laboratory value responses to tocilizumab in Case 1 (A), Case 2 (B), and Case 3 (C). Platelet counts and Absolute neutrophil
counts (ANC) (left column), and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels (right column) from initiation of
tocilizumab at Day 0. Arrow indicates dosing of tocilizumab. Note differing x-axis intervals among the three cases.
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A 3 year-old Caucasian girl had a 2 year history of sJIA,
complicated by two previous episodes of macrophage acti-
vation syndrome (MAS) as well as chronic hepatitis with
liver biopsy showing nonspecific chronic portal triaditis
and minimal periportal reticulin fibrosis. Because she con-
tinued to exhibit fever, rash and serositis while on steroids
and anakinra (up to 8 mg/kg/day), twice monthly TCZ
was initiated at 12 mg/kg/dose and anakinra was discon-
tinued. Two weeks after her initial infusion, the platelet
count dropped from 150 k to 29 k/μL, while the ANC
remained normal (Figure 1B). She had stable hepatosple-
nomegaly and her aspartate transaminase (AST) and ala-
nine transaminase (ALT) were about twice normal, which
was her baseline due to her chronic hepatitis. Infectious
work-up for bacterial and viral sources, including adeno-
virus, Epstein-Barr virus (EBV), human herpesvirus 6
(HHV-6), cytomegalovirus (CMV), and enterovirus was
negative. Platelets were administered, TCZ was held, and
her prednisone dose (2 mg/kg) remained unchanged.Given the rapid decline in platelet count, we considered
MAS. Her soluble interleukin-2 receptor (sIL-2R) level
was 5451 U/ml (reference range 406–1100 U/ml). Al-
though the hemoglobin dropped from 12.8 to 10.4 g/dL,
fibrinogen went from normal to 173 mg/dL, and ferritin
peaked at 12,900 ng/mL, these laboratory parameters
improved without any therapeutic intervention. The
patient’s thrombocytopenia eventually resolved and she
subsequently developed labs indicative of a flare of sJIA:
leukocytosis (white blood cell count increased from 8,500
to 17,100 cells/ μL), resolution of thrombocytopenia
(platelet count went from 65 k after transfusion to 209 k/
μL), and an increase in inflammatory markers (ESR went
from 31 to 80 and CRP from 1.8 to 5.6 mg/dL). Due to
the significant thrombocytopenia, TCZ was not restarted,
but rather, anakinra was resumed.
Case 3
A 15 year-old Caucasian male with a history of sJIA for
11 years had failed to achieve long-term remission with
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kinra, and IVIG. He’d had 3 previous episodes of MAS.
After two doses of twice monthly TCZ (8 mg/kg/dose),
his ANC dropped to 280 cells/μL, platelet count to 55 k/
μL, and Hgb to 8.7 g/dL (Figure 1C). He had stable
splenomegaly and his liver enzymes, CRP, ESR, ferritin,
and fibrinogen were normal. Bacterial and viral studies, in-
cluding EBV, HHV-6, CMV, enterovirus, and parvovirus
B19 were negative. TCZ and cyclosporine (4 mg/kg/day)
were held. Two weeks later the pancytopenia resolved and
cyclosporine was resumed.
Discussion
Three published studies have evaluated the efficacy and
safety of TCZ in patients with sJIA [3-5]. A fourth study,
the TENDER trial, is currently in the extension phase [6].
Patients with a history of MAS were included in two of
the published studies as long as features of MAS were not
present in the weeks leading up to initiation of TCZ [3,5].
The TENDER trial had no such exclusion criteria. Woo,
et al. found that most children had lymphopenia after a
single infusion of 2, 4, or 8 mg/kg of TCZ, although many
had low lymphocyte counts prior to treatment. No other
cytopenias were reported with the exception of transient
pancytopenia in one patient at week seven, not requiring
withdrawal from the study [4]. Yokota, et al. also used a
dose of 2, 4, or 8 mg/kg of TCZ every two weeks for three
total doses without report of cytopenias [5]. The most re-
cently published study used 8 mg/kg of TCZ every two
weeks with an open-label extension phase of at least
48 weeks. They had one patient who developed transami-
nitis and neutropenia (963 cells/μL) in association with
EBV mononucleosis two weeks after the fifth infusion of
TCZ. Laboratory values normalized after three weeks and
the patient resumed treatment with TCZ [3].
Our experience in using TCZ has not been reflective
of the published studies. We describe adverse reactions
with significant cytopenias in three children treated with
TCZ. Notably, two children (cases 2 and 3) who devel-
oped cytopenias with TCZ had a history of MAS. The
cytopenias in cases 2 and 3 occurred after one to two
doses, and in both instances, were characterized by
thrombocytopenia. This is in contrast to case 1, who
developed isolated neutropenia after her 5th infusion.
Case 2, in addition to thrombocytopenia, also developed
anemia, hypofibrinogenemia, and hyperferritinemia,
which could be consistent with MAS, although these lab
abnormalities resolved without any intervention. Follow-
ing this normalization, her laboratory values sub-
sequently became consistent with an inflammatory
response, suggesting that after a washout period of TCZ,
her sJIA flared.
IL-6 is an important acute phase response protein that
increases neutrophil and platelet counts, fibrinogen, andthe ESR. The literature thus far has not described cyto-
penias requiring TCZ modification. However, our ex-
perience suggests that cytopenias with TCZ are more
common than previously documented. One explanation
for the discrepancy between the literature and our ex-
perience could be that some of the dosages used in these
studies were lower than that currently recommended by
the manufacturer. In the cases described above, treat-
ment with TCZ resulted in cytopenias that were more
rapid in onset in those with a prior history of MAS
(cases 2 and 3). Notably, thrombocytopenia occurred
with both of these children, which is in contrast to the
isolated neutropenia seen in case 1. It is possible that
cases 2 and 3 had subclinical MAS, which was balanced
by the acute phase response. Addition of IL-6 blockade
by TCZ altered this balance, leading to cytopenias. The
concept of subclinical MAS is supported by the finding
that children with sJIA who otherwise do not meet cri-
teria for MAS demonstrate the presence of hemophago-
cytosis on bone marrow aspirate [7]. We do not believe
TCZ induces MAS in such patients. Rather, the effects
of TCZ can make it difficult to distinguish from ongoing
hemophagocytosis in MAS. A recent publication has
also suggested that TCZ can make MAS more difficult
to diagnose due to alteration of laboratory studies [8].
As neutropenia can be seen after TCZ administration,
perhaps development of thrombocytopenia is a more
helpful marker of ongoing subclinical MAS as seen in
our case series.
Conclusions
Our experience suggests that additional caution in TCZ
use for children with a history of MAS is warranted to
avoid serious adverse events related to cytopenias. Such
measures might include a dose reduction or modifica-
tion of the frequency with which TCZ is given.
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